All Articles

Bayer’s sevabertinib receives accelerated FDA approval for HER2-mutated NSCLC, offering new hope for a previously underserved patient population. Experts discuss the drug's potential and the evolving landscape of targeted cancer therapies.

A new UNICEF report reveals Canada's declining performance in child welfare, prompting youth advocates to urge Ottawa for a national strategy addressing poverty, healthcare, and climate change.

A new executive program blends academic rigor with real-world insights from Manchester City, aiming to train the next generation of sports business leaders for an increasingly globalized industry.

Controlled environment agriculture company expands retail footprint in Northeast, riding consumer demand for fresh, locally-sourced food while navigating a challenging financial landscape.

New Delhi summit signals a shift for India's pharmaceutical industry, emphasizing partnerships, R&D, and a move beyond generics to become a global 'Pharma Powerhouse' by 2047.

Florida’s housing market is cooling, but LGI Homes is doubling down on affordability with Fulton Meadows, a new single-family community in Lakeland. Can the builder’s ‘CompleteHome’ package navigate changing buyer preferences and economic headwinds?

A new biotechnology-based mouth spray, Murnia®, is entering the market, offering a unique solution for persistent oral dryness by focusing on natural hydration without stimulating saliva – a shift from traditional remedies.

A breakthrough antibody offering strong protection against RSV is gaining traction in Canada. While clinical trials show promising results, affordability and equitable access remain key challenges for widespread implementation.

The collaboration between Johns Hopkins Health Plans and Inova Health will bring expanded Medicare Advantage options to Fairfax, Loudoun, and Prince William counties, intensifying competition in a growing market.

Octopus AIM VCT's repurchase of nearly 1.4 million shares highlights a strategic capital allocation approach within the Venture Capital Trust sector, balancing shareholder value with investment opportunities.

A new weight loss supplement promising rapid results is drawing skepticism as questions emerge regarding its clinical validation, company registration, and scientific backing. Is this a breakthrough or buyer beware?

Lemon Seed Marketing's annual conference brings together home service professionals to explore branding and marketing tactics tailored to a rapidly evolving industry. The event, set in Lufkin, Texas, aims to provide actionable strategies for growth.

Plus Therapeutics secures national coverage with Humana, broadening access to CNSide®, a cutting-edge test for diagnosing and monitoring brain metastasis. This coverage, following UnitedHealthcare’s approval, signals a shift towards advanced diagnostics in cancer care.

Radiopharmaceutical developer Perspective Therapeutics is hitting the investor circuit, showcasing its alpha-emitting cancer therapies. With a crowded field and recent M&A activity, the company is seeking funding to advance its pipeline and scale manufacturing.

New appointments to Plan International Canada’s board come at a critical juncture, as global crises exacerbate inequalities and threaten progress in girls’ education, safety, and empowerment. The organization aims to bolster strategic direction and impact.

Beth Toenies’ recognition as a 'Woman of Inspiration' shines a light on the growing impact of female leadership within the franchise sector and BELFOR Franchise Group’s commitment to diversity.

A joint venture between energy giants Enterprise and ExxonMobil expands NGL pipeline capacity out of the Permian Basin, signaling confidence in long-term growth and intensifying competition in the midstream sector.

Millennium Systems International’s (MSI) consistent recognition as a top workplace—and leader in beauty/wellness software—highlights a growing trend: remote-first innovation and a focus on employee wellbeing.

The antibody-drug conjugate market is experiencing rapid growth, fueled by innovative therapies and expanding applications. Experts predict a $36B+ market by 2034, but challenges remain in accessibility and treatment resistance.

SciSparc Ltd. and Clearmind Medicine Inc. are advancing a novel approach to treating depression with a non-hallucinogenic therapy. A recently filed patent application signals a commitment to innovative CNS treatments.